{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:48:40Z","timestamp":1792684120577,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010754","name":"National Healthcare Group","doi-asserted-by":"publisher","award":["NHG-CSCS\/15007"],"award-info":[{"award-number":["NHG-CSCS\/15007"]}],"id":[{"id":"10.13039\/501100010754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.schres.2023.10.001","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T04:05:08Z","timestamp":1696997108000},"page":"66-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Once-daily versus divided dosing regimens of clozapine: A cross-sectional study in Singapore"],"prefix":"10.1016","volume":"268","author":[{"given":"Zixu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie Yin","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen Mei","family":"See","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmaine","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Tat","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2023.10.001_bb0005","first-page":"Cd006633","article-title":"Clozapine versus other atypical antipsychotics for schizophrenia","volume":"11","author":"Asenjo Lobos","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.schres.2023.10.001_bb0010","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1192\/pb.21.4.224","article-title":"Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications","volume":"21","author":"Atkins","year":"1997","journal-title":"Psychiatr. Bull."},{"issue":"8","key":"10.1016\/j.schres.2023.10.001_bb0015","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1176\/ps.49.8.1095","article-title":"Patients' preferences about medication dosing regimens","volume":"49","author":"Balon","year":"1998","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2023.10.001_bb0020","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2023.10.001_bb0025","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2023.10.001_bb0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.schres.2023.10.001_bb0035","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"issue":"1\u20133","key":"10.1016\/j.schres.2023.10.001_bb0040","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.schres.2007.12.470","article-title":"The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder","volume":"100","author":"Byerly","year":"2008","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2023.10.001_bb0045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1469-8749.1989.tb04000.x","article-title":"Efficacy of benztropine therapy for drooling","volume":"31","author":"Camp-Bruno","year":"1989","journal-title":"Dev. Med. Child Neurol."},{"issue":"2","key":"10.1016\/j.schres.2023.10.001_bb0050","doi-asserted-by":"crossref","DOI":"10.1111\/appy.12384","article-title":"Using therapeutic drug monitoring to personalize clozapine dosing in Asians","volume":"12","author":"de Leon","year":"2020","journal-title":"Asia Pac. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2023.10.001_bb0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels","volume":"55","author":"de Leon","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.10.001_bb0060","series-title":"Medical Genetics Summaries","article-title":"Clozapine therapy and CYP genotype","author":"Dean","year":"2012"},{"key":"10.1016\/j.schres.2023.10.001_bb0065","unstructured":"Devon Partennersio NHS Trust, n.d. Clinical Protocol for the Safe Use of Clozapine Clinical Protocol - CP19. https:\/\/www.dpt.nhs.uk\/download\/jMKd5kFfYn (accessed August 22, 2023)."},{"issue":"3","key":"10.1016\/j.schres.2023.10.001_bb0070","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s11747-011-0300-3","article-title":"Guidelines for choosing between multi-item and single-item scales for construct measurement: a predictive validity perspective","volume":"40","author":"Diamantopoulos","year":"2012","journal-title":"J. Acad. Mark. Sci."},{"issue":"3","key":"10.1016\/j.schres.2023.10.001_bb0075","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4088\/JCP.v65n0311","article-title":"Adherence to conventional and atypical antipsychotics after hospital discharge","volume":"65","author":"Diaz","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.001_bb0080","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/656370","article-title":"Second-generation antipsychotics and extrapyramidal adverse effects","volume":"2014","author":"Divac","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.schres.2023.10.001_bb0085","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1192\/bjp.182.6.505","article-title":"Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK","volume":"182","author":"Duggan","year":"2003","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.10.001_bb0090","first-page":"Cd000059","article-title":"Clozapine versus typical neuroleptic medication for schizophrenia","volume":"2009","author":"Essali","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.schres.2023.10.001_bb0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.18433\/J3KC7P","article-title":"Literature values of terminal half-lives of clozapine are dependent on the time of the last data point","volume":"17","author":"Fang","year":"2014","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.schres.2023.10.001_bb0100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jpsychires.2014.01.009","article-title":"Toward a more parsimonious assessment of neurocognition in schizophrenia: a 10-minute assessment tool","volume":"52","author":"Fervaha","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2023.10.001_bb0105","series-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I\/ P)","author":"First","year":"2002"},{"key":"10.1016\/j.schres.2023.10.001_bb0110","unstructured":"Food and Drug Administration, 2017. CLOZARIL\u00ae(Clozapine) Tablets, for Oral Use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/019758s084lbl.pdf (accessed August 28, 2023)."},{"key":"10.1016\/j.schres.2023.10.001_bb0115","unstructured":"Freudenreich, O., 2023. Guidelines for Prescribing Clozapine in Schizophrenia. https:\/\/imsva91-ctp.trendmicro.com:443\/wis\/clicktime\/v1\/query?url=https%3a%2f%2fwww.uptodate.com%2fcontents%2fguidelines%2dfor%2dprescribing%2dclozapine%2din%2dschizophrenia%2fprint%3fsearch%3dclozapine%26source%3dsearch%5fresult%26selectedTitle%3d2%7e107%26usage%5ftype%3ddefault%26display%5frank%3d1&umid=B566540B-0020-E306-A8F1-C71E37BDFEDC&auth=6e3fe59570831a389716849e93b5d483c90c3fe4-6834dcce726c5fcac1e0d2a00b9fb9102a28895a (accessed July 16, 2023)."},{"issue":"5","key":"10.1016\/j.schres.2023.10.001_bb0120","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2023.10.001_bb0125","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1176\/ajp.149.9.1148","article-title":"Revising axis V for DSM-IV: a review of measures of social functioning","volume":"149","author":"Goldman","year":"1992","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.10.001_bb0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00002018-200730010-00005","article-title":"Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003","volume":"30","author":"Haas","year":"2007","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.schres.2023.10.001_bb0135","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World J. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2023.10.001_bb0140","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/13651500310002986","article-title":"The use of the Simpson Angus Scale for the assessment of movement disorder: a training guide","volume":"7","author":"Hawley","year":"2003","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"12","key":"10.1016\/j.schres.2023.10.001_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243437","article-title":"The side effect profile of clozapine in real world data of three large mental health hospitals","volume":"15","author":"Iqbal","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.schres.2023.10.001_bb0155","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"issue":"9","key":"10.1016\/j.schres.2023.10.001_bb0160","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2023.10.001_bb0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2023.10.001_bb0170","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20r13503","article-title":"Single versus multiple daily dosing regimens of psychotropic drugs for psychiatric disorders: a systematic review and Meta-analysis","volume":"82","author":"Kikuchi","year":"2021","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2023.10.001_bb0175","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/JCP.0000000000001492","article-title":"Clozapine once-daily versus divided dosing regimen: a cross-sectional study in Japan","volume":"42","author":"Kitagawa","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2023.10.001_bb0180","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/ajp.152.2.179","article-title":"Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients","volume":"152","author":"Kronig","year":"1995","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2023.10.001_bb0185","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19r13113","article-title":"Dissociation in pharmacokinetic attenuation between central dopamine D2 receptor occupancy and peripheral blood concentration of antipsychotics: a systematic review","volume":"81","author":"Kurose","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.001_bb0190","article-title":"Clozapine once- versus multiple-daily dosing: a two-center cross-sectional study, systematic review and meta-analysis","author":"Kuzo","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.schres.2023.10.001_bb0195","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/JCP.0000000000001384","article-title":"A chart audit study of clozapine utilization in early psychosis","volume":"41","author":"Leclerc","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.schres.2023.10.001_bb0200","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/070674371506001107","article-title":"Subtyping schizophrenia by treatment response: antipsychotic development and the central role of positive symptoms","volume":"60","author":"Lee","year":"2015","journal-title":"Can. J. Psychiatr."},{"issue":"2 Suppl","key":"10.1016\/j.schres.2023.10.001_bb0205","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2023.10.001_bb0210","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"issue":"9657","key":"10.1016\/j.schres.2023.10.001_bb0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.schres.2023.10.001_bb0220","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/schbul\/sbu001","article-title":"Dose equivalents for second-generation antipsychotics: the minimum effective dose method","volume":"40","author":"Leucht","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.10.001_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2021.102732","article-title":"Large-scale evaluation of the Positive and Negative Syndrome Scale (PANSS) symptom architecture in schizophrenia","volume":"62","author":"Lim","year":"2021","journal-title":"Asian J. Psychiatr."},{"issue":"4","key":"10.1016\/j.schres.2023.10.001_bb0230","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.10.001_bb0235","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00002820-198906000-00012","article-title":"Validity and reliability of the Constipation Assessment Scale","volume":"12","author":"McMillan","year":"1989","journal-title":"Cancer Nurs."},{"issue":"4","key":"10.1016\/j.schres.2023.10.001_bb0240","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4088\/JCP.v65n0408","article-title":"The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update","volume":"65","author":"Miller","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2023.10.001_bb0245","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/pgs-2022-0006","article-title":"The role of alcohol intake in the pharmacogenetics of treatment with clozapine","volume":"23","author":"Monroy-Jaramillo","year":"2022","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.schres.2023.10.001_bb0250","unstructured":"Novartis Pharmaceuticals Canada Inc., 2011. Clozapine Tablets. https:\/\/www.novartis.ca\/sites\/www.novartis.ca\/files\/clozaril_scrip_e.pdf (accessed April 28, 2023)."},{"issue":"3","key":"10.1016\/j.schres.2023.10.001_bb0255","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"issue":"2","key":"10.1016\/j.schres.2023.10.001_bb0260","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mehy.2013.11.043","article-title":"Clozapine administered once versus twice daily: does it make a difference?","volume":"82","author":"Procyshyn","year":"2014","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.schres.2023.10.001_bb0145","unstructured":"Queensland Health, 2021. Safe and quality use of clozapine in mental health alcohol and other drugs (MHAOD) services. https:\/\/www.health.qld.gov.au\/system-governance\/policies-standards\/guidelines\/clozapine-safe-quality-use (accessed 26 April 2023)."},{"issue":"1","key":"10.1016\/j.schres.2023.10.001_bb0265","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1742-7843.2004.pto_940104.x","article-title":"Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients","volume":"94","author":"Raaska","year":"2004","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"1\u20133","key":"10.1016\/j.schres.2023.10.001_bb0270","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.schres.2006.11.015","article-title":"The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia","volume":"90","author":"Remington","year":"2007","journal-title":"Schizophr. Res."},{"issue":"9","key":"10.1016\/j.schres.2023.10.001_bb0275","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0706743717720448","article-title":"Guidelines for the pharmacotherapy of schizophrenia in adults","volume":"62","author":"Remington","year":"2017","journal-title":"Can. J. Psychiatr."},{"issue":"2","key":"10.1016\/j.schres.2023.10.001_bb0280","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/JCP.0000000000001018","article-title":"Clozapine metabolism in east Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review","volume":"39","author":"Ruan","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.10.001_bb0285","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1017\/S1742646413000332","article-title":"Drug interactions affecting clozapine levels","volume":"11","author":"Singh","year":"2015","journal-title":"J. Psychiatr. Intensive Care"},{"issue":"8","key":"10.1016\/j.schres.2023.10.001_bb0290","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.4088\/JCP.08m04495","article-title":"Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study","volume":"70","author":"Sockalingam","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2023.10.001_bb0295","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1017\/S1092852912000806","article-title":"Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses","volume":"18","author":"Souza","year":"2013","journal-title":"CNS Spectr."},{"issue":"1","key":"10.1016\/j.schres.2023.10.001_bb0300","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s002130050028","article-title":"Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics","volume":"148","author":"Spina","year":"2000","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2023.10.001_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.10.011","article-title":"Results of phase 3 of the CATIE schizophrenia trial","volume":"107","author":"Stroup","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.001_bb0310","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jpsychires.2016.06.005","article-title":"A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD)","volume":"80","author":"Takeuchi","year":"2016","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.schres.2023.10.001_bb0315","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/acps.12593","article-title":"Clozapine administration in clinical practice: once-daily versus divided dosing","volume":"134","author":"Takeuchi","year":"2016","journal-title":"Acta Psychiatr. Scand."},{"issue":"5","key":"10.1016\/j.schres.2023.10.001_bb0320","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/schbul\/sbab016","article-title":"Antipsychotic medications: enhancing use to improve outcomes","volume":"47","author":"Takeuchi","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.10.001_bb0325","unstructured":"The Netherlands Clozapine Collaboration Group, n.d. Guideline for the Use of Clozapine. https:\/\/imsva91-ctp.trendmicro.com\/wis\/clicktime\/v1\/query?url=http%3a%2f%2fwww.clozapinepluswerkgroep.nl%2fwp-content%2fuploads%2f2013%2f07%2fGuideline-for-the-use-of-Clozapine-2013.pdf&umid=B566540B-0020-E306-A8F1-C71E37BDFEDC&auth=6e3fe59570831a3897168 (accessed August 26, 2023)."},{"issue":"9690","key":"10.1016\/j.schres.2023.10.001_bb0330","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.schres.2023.10.001_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004216","article-title":"Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine","volume":"4","author":"Tsuda","year":"2014","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.schres.2023.10.001_bb0340","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4088\/JCP.08r04171","article-title":"Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms","volume":"70","author":"Uchida","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.001_bb0345","unstructured":"Viatris, 2023. New Zealand Data Sheet Clozaril\u00ae. https:\/\/www.medsafe.govt.nz\/profs\/datasheet\/c\/clozariltab.pdf (accessed August 22, 2023)."},{"issue":"6","key":"10.1016\/j.schres.2023.10.001_bb0350","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/acps.13228","article-title":"Impact of smoking behavior on clozapine blood levels - a systematic review and meta-analysis","volume":"142","author":"Wagner","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"issue":"2","key":"10.1016\/j.schres.2023.10.001_bb0355","first-page":"113","article-title":"The European Psychiatric Association (EPA) guidance on suicide treatment and prevention","volume":"14","author":"Wasserman","year":"2012","journal-title":"Neuropsychopharmacol. Hung."},{"key":"10.1016\/j.schres.2023.10.001_bb0360","first-page":"679","article-title":"Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics","volume":"6","author":"Witticke","year":"2012","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.schres.2023.10.001_bb0365","first-page":"1002235","article-title":"Cigarette smoking, coffee consumption, alcohol intake, and clozapine metabolism: a Mendelian randomization study","volume":"13","author":"Zeng","year":"2022","journal-title":"Front. Psychol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423003547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423003547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T19:44:41Z","timestamp":1778701481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423003547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":73,"alternative-id":["S0920996423003547"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.10.001","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Once-daily versus divided dosing regimens of clozapine: A cross-sectional study in Singapore","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}